To create a healthier future for patients with life-threatening diseases, Engitix has pioneered a world-leading and best-in-class human extracellular matrix (ECM)-based discovery platform to identify novel therapeutic targets and biomarkers for treating patients with organ fibrosis and solid tumours.

The Engitix technology leverages patient-derived, organ and disease-specific ECM scaffolds. These materials enable disease-relevant, 3D co-culture cellular systems to be established to study the complex molecular signals driving fibrotic diseases and cancers. These 3D assay systems recapitulate significant facets of disease biology to enable and accelerate the discovery of novel therapeutic mechanisms.

The Engitix platform is highly translational and allows a deep understanding of the disease biology to guide the discovery process. Engitix has now established a portfolio of therapeutic programmes that aims to address the high, clinical unmet need for patients with fibrotic diseases and cancers. Our patient-centric approach aims to more accurately predict the therapeutic efficacy of drug candidate to reduce the attrition of assets in our portfolio as the programmes progress through clinical development.

In addition to our internal portfolio, we have discovery partnerships deals with Takeda in liver fibrosis and IBD (worth more than $800MM biodollars) and Dompe’ Farmaceutici.